Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Not Yet Opened 03-16 16:00:00 EDT

428.34

+3.65

+0.86%

High437.76	Low423.49	Vol15.62M
Open426.57	D1 Closing424.69	Amplitude3.36%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O202.53M	T/O Rate--	Tradable Shares0.00
P/B2.345284	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":428.3356,"timestamp":1773691199999,"preClose":424.6903,"halted":0,"volume":15621053,"delay":0,"changeRate":0.008583,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":3.645294,"latestTime":"03-16 16:00:00 EDT","open":426.56787,"high":437.76196,"low":423.48602,"amount":202531888.133751,"amplitude":0.033615,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773754200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.345284,"peRate":-6.748349,"turnoverRate":0.020938,"increases":3,"decrements":2,"flats":0,"marketCap":9196926576,"floatMarketCap":8533610592},"requestUrl":"/m/hq/s/BK4556/tweets","defaultTab":"tweets","newsList":[{"id":"2620491059","title":"Crispr Therapeutics Completes $600 Million Convertible Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491059?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:34","pubTimestamp":1773693281,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics AG ( ($CRSP) ) just unveiled an announcement. On March 16, 2026, CRISPR Therapeutics AG completed a $600 million private offeri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-completes-600-million-convertible-notes-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-completes-600-million-convertible-notes-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","LENZ","BK4539","BK4611","BK4139","BK4588","BK4585","LU1861558580.USD","BK4556","BK4007","CRSP"],"gpt_icon":0},{"id":"2619961469","title":"Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619961469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619961469?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:50","pubTimestamp":1773669007,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), Pelthos ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XBI","BK4581","BK4556","BK4611","BK4112","BK4139","BLSG","LABU","LU0128526141.USD","LU1861559042.SGD","BEAM","BK4137","BK4505","LU0029874061.USD","BK4585","BLSX","LU1861558580.USD","BK4535","PTHS"],"gpt_icon":0},{"id":"2619912669","title":"CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2619912669","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619912669?lang=en_us&edition=fundamental","pubTime":"2026-03-14 18:21","pubTimestamp":1773483682,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution.\nThe company highlights a threefold increase in projected patient initiations for 2025, signaling growing real world adoption of CASGEVY.\nAlongside CASGEVY traction, CRISPR Therapeutics advances new gene editing programs and partnerships, expanding its clinical pipeline.\n\nCRISPR Therapeutics, trading at $48.75, is moving further into a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4097","CRSP","LU1861559042.SGD","BK4611","PRGS","BK4556","BK4139","LU1861558580.USD","BK4585","BK4588","LU2065732104.USD"],"gpt_icon":0},{"id":"2619148240","title":"Sangamo Therapeutics Inc  expected to post a loss of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619148240","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619148240?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:53","pubTimestamp":1773435186,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc  expected to post a loss of6cents a share - Earnings Preview Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected to  show a rise in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N401234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","SGMO"],"gpt_icon":0},{"id":"2619110236","title":"Press Release: Morningstar, Inc. Declares Quarterly Dividend of 50 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2619110236","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619110236?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:15","pubTimestamp":1773432900,"startTime":"0","endTime":"0","summary":"The board of directors of Morningstar, Inc. , a leading provider of independent investment insights, today declared a quarterly dividend of 50 cents per share, consistent with the dividend paid in January. The dividend is payable April 30, 2026, to shareholders of record as of April 3, 2026. Please contact investors@morningstar.com with any questions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4139","CRSP","LU1861559042.SGD","BK4556","BK4611","MORN","BK4598","LU2065731478.USD","BK4588","BK4112","LU1861558580.USD","BK4585"],"gpt_icon":0},{"id":"2619597111","title":"Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS","url":"https://stock-news.laohu8.com/highlight/detail?id=2619597111","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619597111?lang=en_us&edition=fundamental","pubTime":"2026-03-13 10:12","pubTimestamp":1773367952,"startTime":"0","endTime":"0","summary":"Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio moves on Thursday, March 12, according to the firm’s daily tra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/cathie-wood-invests-over-10m-in-crispr-and-payp-stocks-trims-stakes-in-ter-and-ions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/cathie-wood-invests-over-10m-in-crispr-and-payp-stocks-trims-stakes-in-ter-and-ions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","ARKQ","IONS","PAYP","IE00BN0W2V16.EUR","LU0957808578.USD","BK4556","ARKK","BK4548","ARKG","BK4543","BK4147","ARKW","LU1861558580.USD","TER","IE00BN0W2T93.GBP","BK4588","LU1642822529.SGD","TERG","LU0444971666.USD","ARKF","BK4544","LU1815336760.USD","BK4585","ARKX","LU1861559042.SGD","CRSP","IE00BN0W2W23.USD","BK4139"],"gpt_icon":0},{"id":"2618594070","title":"CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2618594070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618594070?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:10","pubTimestamp":1773234600,"startTime":"0","endTime":"0","summary":"Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made targeted buys in biotech and cryptocurrency sectors on Tuesday, March 10, capitalizing o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/crsp-solq-cathie-woods-ark-buys-the-dip-in-crispr-and-solana-staking-etf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/crsp-solq-cathie-woods-ark-buys-the-dip-in-crispr-and-solana-staking-etf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRSP","BK4585","ARKQ","BK4556","BK4139","BK4611","ARKX","BK4544","LU1861558580.USD","BK4588","LU1861559042.SGD","SOLT","ARKG","ARKK","FDN","BK4550"],"gpt_icon":0},{"id":"2618094132","title":"Crispr Therapeutics prices upsized convertible senior notes offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618094132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618094132?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:16","pubTimestamp":1773227780,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) announced the pricing of $550M aggregate principal amount of its convertible senior notes due 2031 in a private offering...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","CRSP","BK4556","BK4611","LENZ","BK4585","LU1861558580.USD","BK4588","BK4539","LU1861559042.SGD"],"gpt_icon":0},{"id":"2618404913","title":"Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2618404913","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618404913?lang=en_us&edition=fundamental","pubTime":"2026-03-11 14:02","pubTimestamp":1773208935,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. (EDIT) has disclosed a new risk, in the Regulation category. Disruptions at the FDA and other government agencies could materi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-disruptions-at-fda-threaten-editas-medicines-gene-editing-timelines-and-commercial-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-disruptions-at-fda-threaten-editas-medicines-gene-editing-timelines-and-commercial-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","LABU","BK4139","EDIT","BK4585","BK4588"],"gpt_icon":0},{"id":"2618996935","title":"Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2618996935","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618996935?lang=en_us&edition=fundamental","pubTime":"2026-03-11 09:05","pubTimestamp":1773191109,"startTime":"0","endTime":"0","summary":"21:03 EDT Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ultimate source for rea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-281k-shares-of-crispr-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-281k-shares-of-crispr-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKX","LENZ","BK4007","BK4585","CRSP","LU1861559042.SGD","BK4556","ARKQ","BK4588","LU1861558580.USD","BK4539","BK4611","BK4544","ARKG","ARKK","BK4139"],"gpt_icon":0},{"id":"2618574049","title":"What's Going On With CRISPR Therapeutics Stock Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618574049","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618574049?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:56","pubTimestamp":1773161760,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshadowing recent momentum from Casgevy uptake and fourth-quarter revenue growth.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/10/Crispr-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/10/Crispr-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51166078/whats-going-on-with-crispr-therapeutics-stock-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51166078/whats-going-on-with-crispr-therapeutics-stock-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4585","CRSP","BK4556","LU1861558580.USD","BK4139","BK4588","BK4611","LU1861559042.SGD"],"gpt_icon":0},{"id":"2618952795","title":"Crispr Therapeutics falls -9.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618952795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618952795?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:05","pubTimestamp":1773158715,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics (CRSP) is down -9.2%, or -$5.38 to $53.40. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-falls-9-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-falls-9-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","BK4539","BK4585","LU1861558580.USD","BK4007","CRSP","BK4588","LENZ","LU1861559042.SGD","BK4139","BK4556"],"gpt_icon":0},{"id":"2618516379","title":"Crispr Therapeutics Falls on $350M Senior Note Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2618516379","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618516379?lang=en_us&edition=fundamental","pubTime":"2026-03-10 22:43","pubTimestamp":1773153780,"startTime":"0","endTime":"0","summary":"Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes.The stock was down 7.3% at $54.49 in Tuesday morning trading. The stock has gained 25% in the past year.The biopharmaceutical company, which focuses on gene-based medicines, said it plans to sell the convertible senior notes, due 2031, in a private offering to qualified institutional buyers. It said it will use the proceeds for general corporate purposes.Initial purchasers of the notes will have a 13-day option to buy an additional $52.5 million in senior notes, the company said.The notes will accrue interest payable on March 1 and Sept. 1 of each year, beginning Sept. 1 2026, and ending March 1, 2031. Notes can also be converted into common shares.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4611","LU1861559042.SGD","BK4588","CRSP","LU1861558580.USD","LENZ","BK4556","BK4585","BK4139"],"gpt_icon":0},{"id":"2618342929","title":"CRISPR Therapeutics plans USD 350 million convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2618342929","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618342929?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:09","pubTimestamp":1773140981,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics said it plans a private offering of USD 350 million of convertible senior notes due 2031. The company expects to give initial purchasers an option to buy up to an additional USD 52.5 million of notes, bringing the potential total to USD 402.5 million. The notes are senior unsecured obligations, with interest payable semiannually starting Sept. 1, 2026. Proceeds are expected to be used for general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL3sbqch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","CRSP","BK4112","NDAQ","IE00B64PRP62.GBP","BK4139","LU1861558580.USD","LU2210150020.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU1861559042.SGD","LU0314104364.USD","BK4611","LU2095319765.USD","BK4556","BK4585","SG9999014039.USD","BK4588","SG9999014013.SGD"],"gpt_icon":0},{"id":"2618934225","title":"CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934225","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934225?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:00","pubTimestamp":1773140400,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, March  10, 2026  (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252625/0/en/CRISPR-Therapeutics-Announces-Proposed-Convertible-Senior-Notes-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","CRSP","BK4585","LU1861558580.USD","BK4588","LU1861559042.SGD","BK4556","BK4139"],"gpt_icon":0},{"id":"2618862689","title":"Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618862689","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618862689?lang=en_us&edition=fundamental","pubTime":"2026-03-10 13:13","pubTimestamp":1773119582,"startTime":"0","endTime":"0","summary":"In recent weeks, Intellia Therapeutics reported long-term Phase 1/2 data for its CRISPR-based HAE candidate lonvoguran ziclumeran and regained FDA clearance to resume Phase 3 testing of its ATTR-CM therapy nexiguran ziclumeran after agreeing to enhanced liver safety monitoring. \nTogether, these updates highlight Intellia’s push to position one-time in vivo gene-editing treatments as alternatives to chronic therapies in serious genetic diseases. \nBuilding on the FDA’s removal of the clinical...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/is-intellia-therapeutics-ntla-turning-regulatory-scrutiny-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/is-intellia-therapeutics-ntla-turning-regulatory-scrutiny-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861558580.USD","BK4551","BK4585","BK4588","BK4535","BK4556","AI","BK4139","BK4587","LU1861559042.SGD","AIYY","NTLA","BK4543","BK4528","BK4023"],"gpt_icon":0},{"id":"2618675478","title":"What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618675478","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618675478?lang=en_us&edition=fundamental","pubTime":"2026-03-10 01:32","pubTimestamp":1773077520,"startTime":"0","endTime":"0","summary":"FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/26/03/51137510/whats-going-on-with-moderna-capricor-other-biotech-stocks-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":"927f9eef172e6c5b2e0a9bbef1328a2b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51137510/whats-going-on-with-moderna-capricor-other-biotech-stocks-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":[".IXIC","IE0009355771.USD","QYLG","CRSP","NQmain","GPIQ","LU0320765992.SGD","BK4585","SLDB","LU0889565916.HKD","QURE","IE00BJJMRZ35.SGD","BK4611","SQQQ","LU0109394709.USD","SRPU","BK4588","JEPQ","QID","MNQmain","USAW.SI","QQQJ","LU1861558580.USD","TSYW.SI","USJW.SI","IE00BFTCPJ56.SGD","NVIW.SI","IE0002141913.USD","QYLD","IE00B2B36J28.USD","TQQQ","LU1861559042.SGD","SRPT","IE00BJT1NW94.SGD","QQQE","PSQ","BK4139","QQQY","CAPR","BK4556","QLD"],"gpt_icon":1},{"id":"2618636625","title":"Sangamo submits ST-920 BLA clinical and preclinical modules to FDA for Fabry disease accelerated approval review","url":"https://stock-news.laohu8.com/highlight/detail?id=2618636625","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618636625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:06","pubTimestamp":1773057985,"startTime":"0","endTime":"0","summary":"Sangamo advanced its rolling BLA submission to the FDA seeking accelerated approval of ST-920 for adults with Fabry disease. The company said it has submitted the preclinical and clinical modules for FDA review. Sangamo also said its antibody assay companion diagnostic was submitted to and accepted by the FDA’s Center for Devices and Radiological Health for Premarket Approval.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL10sQg7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","SG9999014013.SGD","BK4139","SG9999014021.USD","BK4588","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","LU2095319765.USD","BK4112","LU2210149790.SGD","LU2210150020.SGD","BK4556","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2618689625","title":"Sangamo Therapeutics Advances Rolling Submission of Bla to U.S. FDA for St-920 in Fabry Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2618689625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618689625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:05","pubTimestamp":1773057910,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX10P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMO","BK4556"],"gpt_icon":0},{"id":"2618625682","title":"Sangamo Therapeutics:  STAAR Study Demonstrated Positive Mean Annualized Egfr Slope at 52-Weeks Across All Dosed Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625682?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:05","pubTimestamp":1773057910,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX10P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMO","BK4556"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}